The TREX neovascular AMD management protocol used with ranibizumab in the Treat-and-Extend Protocol in Patients with Wet Age-Related Macular Degeneration (TREX-AMD) study resulted in visual and anatomic gains comparable with those obtained with monthly dosing, and most patients randomized to TREX therapy demonstrated a relatively consistent maximum extension interval.Ĭopyright © 2016 American Academy of Ophthalmology. Of the 26 TREX patients (65%) who demonstrated recurrent exudation upon interval extension, the first maximum extension interval was consistent in most eyes (n = 19 ). Among TREX patients completing month 24, 14 (47%) were at an extension interval of 8 weeks or more, and the mean maximum tolerated extension was 8.5 weeks over the course of 2 years. Through month 24, the mean number of injections administered was 25.5 (range, 22-27) and 18.6 (range, 10-25) for the monthly and TREX cohorts, respectively (P < 0.001). Anatomic improvements were similar between the cohorts. No monthly cohort patient lost more than 2 letters, whereas 5 TREX cohort patients (13%) lost at least 15 letters. At month 24, 4 patients (20%) and 12 patients (30%) in the monthly and TREX cohorts, respectively, gained at least 15 letters (P = 0.41). Sixty patients were enrolled and 50 completed month 24, at which point mean ETDRS BCVA letter gains were similar: 10.5 and 8.7 for the monthly and TREX cohorts, respectively (P = 0.64). After interval extension, if recurrent exudative disease was identified, this maximum interval between treatments was rechallenged according to a strict prospective protocol.
Patients with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) of 20/32 to 20/500 (Snellen equivalent) were randomized to receive intravitreal 0.5 mg ranibizumab monthly or, according to a TREX protocol, no less frequently than every 12 weeks. Sixty patients with treatment-naïve neovascular AMD randomized 1:2 to monthly or TREX cohorts.
Prospective, randomized, multicenter clinical trial. Payne has published numerous manuscripts for top ophthalmic journals and has presented his scientific research at many national meetings. Job Responsibilities Perform basic screenings, including but not limited to patient history, visual acuity, and tonometry.To evaluate a prospective treat-and-extend (TREX) management strategy compared with monthly dosing with intravitreal ranibizumab (Lucentis) in neovascular age-related macular degeneration (AMD). Its physicians offer comprehensive and state of the art care in the treatment of vitreous and retinal diseases. Personal protective equipment provided or required Palmetto Retina Center, LLC (PRC) was founded in 2001 and serves central South Carolina. Salary: Competitive and commensurate with experience. Ideal candidate should have 1+ years of experience as an ophthalmic technician, can multi-task, and has the ability to work independently as well as with others.Īttractive benefit package including medical insurance, 401k match, and profit-sharing.
A busy 12 MD Ophthalmology practice specializing in retina diseases is currently seeking an experienced Ophthalmic Technician/Assistant with 1+ years of experience for a full-time position at the Augusta, GA location.
0 kommentar(er)
